Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18671411 | 0.85 | OPRM1 (0.48) | ALDH1A1TSHRMAPK1OPRM1TP53 | |
| SCHEMBL11836555 | 0.84 | METAP1 (0.38) | TSHROPRM1METAP1GRIK1SLC1A3 | |
| SCHEMBL22336496 | 0.80 | ALDH1A1 (0.38) | ALDH1A1TSHRMAPK1OPRM1METAP1 | |
| SCHEMBL24998384 | 0.78 | OPRM1 (0.32) | ALDH1A1TSHRMAPK1OPRM1METAP1 | |
| SCHEMBL7391772 | 0.78 | TSHR (0.33) | ALDH1A1TSHRMAPK1METAP1 | |
| SCHEMBL6398109 | 0.77 | METAP1 (0.32) | ALDH1A1METAP1 | |
| SCHEMBL14754396 | 0.77 | ALDH1A1 (0.35) | ALDH1A1TSHRMAPK1OPRM1METAP1 | |
| SCHEMBL599955 | 0.76 | TSHR (0.40) | TSHROPRM1METAP1 | |
| SCHEMBL21730418 | 0.74 | TSHR (0.31) | TSHR | |
| SCHEMBL11223706 | 0.74 | TSHR (0.31) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577363-B2 | Substituted piperidine compounds | Epizyme, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20170362217-A1 | Substituted Piperidine Compounds | Epizyme, Inc. (US) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577363-B2 | Substituted piperidine compounds | SMYD3, SMYD2, SNRPD3 | ALDH1A1 1032/4885TSHR 4097/4885MAPK1 4237/4885 |
| US-20170362217-A1 | Substituted Piperidine Compounds | SMYD3, SMYD2, SNRPD3 | ALDH1A1 1032/4885TSHR 4097/4885MAPK1 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.